MDxHealth SA (NasdaqCM: MDXH)
Health Care · Biotechnology · BE
$0.21
-64.97% today · -94.8% 1Y
MDxHealth SA (NasdaqCM: MDXH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.71M and employs 364 people.
Over the last twelve months the share price has lost 94.8%, trading between 0.19 and 5.33.
Tweenvest scores MDxHealth SA across four factors: quality 37/100, value 63/100, growth 100/100. Its strongest factor is growth.
MDXH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.71M
- Revenue (TTM)
- $114.02M
- P/E
- —
- EPS
- -0.74
- Dividend yield
- —
- Beta (5Y)
- -518,218.96
- 52-week high
- $5.33
- 52-week low
- $0.19
- Avg volume (3M)
- —
- Shares outstanding
- 95.42M
- Employees
- 364
- Next earnings
- —
About MDxHealth SA
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
- ISIN
- BE0974461940
- Founded
- 2003
- Listed since
- Nov 4, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| APTOCROM Inc.KOSDAQ: A109960 | $20.66M | ₩1,821.00 | -5.50% |
| ProBiotix Health PlcOFEX: PBX | $20.57M | £0.10 | +2.63% |
| Taiwan Advance Bio-Pharmaceutical Inc.TPEX: 4186 | $20.25M | NT$7.30 | -3.31% |
| BCAL Diagnostics LimitedASX: BDX | $20.15M | AU$0.08 | -12.22% |
| Modalis Therapeutics CorporationTSE: 4883 | $19.56M | ¥29.00 | -3.33% |
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
| Resverlogix Corp.TSX: RVX | $19.47M | CA$0.08 | -5.88% |
Figures last refreshed Oct 18, 2026.